Board Change • Jun 02
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 5 highly experienced directors. No independent directors (8 non-independent directors). Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • May 20
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 5 highly experienced directors. No independent directors (8 non-independent directors). Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Jun 10
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 8 non-independent directors. Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Apr 25
Birzeit Pharmaceuticals Company announces Annual dividend, payable on May 15, 2025 Birzeit Pharmaceuticals Company announced Annual dividend of USD 0.0500 per share payable on May 15, 2025, ex-date on April 23, 2025 and record date on April 24, 2025. Board Change • Apr 15
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 8 non-independent directors. Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Apr 09
Birzeit Pharmaceuticals Company, Annual General Meeting, Apr 22, 2025 Birzeit Pharmaceuticals Company, Annual General Meeting, Apr 22, 2025. Location: ramallah Palestinian Authority Board Change • Feb 26
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 8 non-independent directors. Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Oct 29
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.7% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.7% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.8% net profit margin). Reported Earnings • Aug 15
Second quarter 2024 earnings released: EPS: US$0.038 (vs US$0.04 in 2Q 2023) Second quarter 2024 results: EPS: US$0.038 (down from US$0.04 in 2Q 2023). Revenue: US$8.36m (down 23% from 2Q 2023). Net income: US$1.48m (down 11% from 2Q 2023). Profit margin: 18% (up from 15% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. New Risk • Jun 13
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 39% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (4.9% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.9% net profit margin). Reported Earnings • Jun 13
First quarter 2024 earnings released: US$0.04 loss per share (vs US$0.046 profit in 1Q 2023) First quarter 2024 results: US$0.04 loss per share (down from US$0.046 profit in 1Q 2023). Revenue: US$9.07m (down 11% from 1Q 2023). Net loss: US$1.44m (down 181% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. New Risk • Jun 11
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.5% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.0% average weekly change). Reported Earnings • Feb 28
Full year 2023 earnings released: EPS: US$0.16 (vs US$0.20 in FY 2022) Full year 2023 results: EPS: US$0.16 (down from US$0.20 in FY 2022). Revenue: US$43.1m (down 8.3% from FY 2022). Net income: US$6.12m (down 23% from FY 2022). Profit margin: 14% (down from 17% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings. Buy Or Sell Opportunity • Feb 13
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 5.8% to US$4.23. The fair value is estimated to be US$3.51, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.8% over the last 3 years. Earnings per share has declined by 7.4%. Board Change • Jan 29
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Nov 01
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Aug 15
Second quarter 2023 earnings released: EPS: US$0.04 (vs US$0.059 in 2Q 2022) Second quarter 2023 results: EPS: US$0.04 (down from US$0.059 in 2Q 2022). Revenue: US$10.9m (down 2.7% from 2Q 2022). Net income: US$1.67m (down 28% from 2Q 2022). Profit margin: 15% (down from 21% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings. Upcoming Dividend • Apr 05
Upcoming dividend of US$0.10 per share at 2.4% yield Eligible shareholders must have bought the stock before 12 April 2023. Payment date: 11 June 2023. Payout ratio is a comfortable 20% but the company is not cash flow positive. Trailing yield: 2.4%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (6.0%). Higher than average of industry peers (1.7%). Board Change • Nov 18
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Aug 14
Second quarter 2022 earnings released: EPS: US$0.063 (vs US$0.13 in 2Q 2021) Second quarter 2022 results: EPS: US$0.063 (down from US$0.13 in 2Q 2021). Revenue: US$11.2m (down 16% from 2Q 2021). Net income: US$2.30m (down 53% from 2Q 2021). Profit margin: 21% (down from 37% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 18% per year and the company’s share price has also increased by 18% per year. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Upcoming Dividend • Apr 14
Upcoming dividend of US$0.10 per share Eligible shareholders must have bought the stock before 21 April 2022. Payment date: 19 June 2022. Payout ratio is a comfortable 24% but the company is paying out more than the cash it is generating. Trailing yield: 3.1%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (5.5%). Higher than average of industry peers (1.7%). Reported Earnings • Feb 21
Full year 2021 earnings: Revenues in line with analyst expectations Full year 2021 results: Revenue: US$45.5m (up 27% from FY 2020). Net income: US$12.1m (up 64% from FY 2020). Profit margin: 27% (up from 21% in FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 6% per year. Board Change • Feb 21
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Feb 18
Full year 2021 earnings: Revenues in line with analyst expectations Full year 2021 results: Revenue: US$45.5m (up 27% from FY 2020). Net income: US$12.1m (up 64% from FY 2020). Profit margin: 27% (up from 21% in FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 4% per year. Reported Earnings • Jun 05
First quarter 2021 earnings released: EPS US$0.05 (vs US$0.093 in 1Q 2020) The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$7.58m (down 9.9% from 1Q 2020). Net income: US$908.0k (down 50% from 1Q 2020). Profit margin: 12% (down from 22% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.